Clinical trials
Amyloid clinical trials
Below are recruiting amyloid clinical trials, each written for real people, not researchers. We’re tracking 89 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90 - NCT07232459Recruiting
PET imaging for amyloidosis in the heart
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
Hefei, AnhuiAges 18 years+ - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT07215715Recruiting
Heart ultrasound study for older adults with heart failure
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Boston, MassachusettsAges 60 years+ - NCT07154394Recruiting
Heart amyloid and function in Alzheimer's disease
This study examines whether amyloid plaques in the heart affect heart function in people with Alzheimer's disease. It uses brain amyloid PET and MRI scans to explore a potential link.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT04776824Recruiting
Swiss registry for people with amyloidosis and possible heart involvement
This trial is a registry that collects health information from people with amyloidosis, including cases where the heart may be involved. Sharing your medical details can help researchers learn how this condition affects patients and may guide future care.
BaselAges 18 years+ - NCT07142278RecruitingPhase 1
Alzheimer's vaccine study for healthy adults ages 40 to 65
This trial tests an experimental vaccine (DUVAX) that targets two proteins linked to Alzheimer's disease: amyloid-beta and tau. It is an early-stage study to check safety and see how the body responds, aiming to prevent or delay the disease.
Miami Lakes, FloridaAges 40–65 - NCT06338696Recruiting
Thailand ATTR-CM patient registry
This registry collects information from people with ATTR-CM, a condition where abnormal protein builds up in the heart. By joining, you help researchers learn more about the disease and improve future care.
BangkokAges 18–100 - NCT07110844RecruitingPhase 2
Teclistamab with Daratumumab for Newly Diagnosed AL Amyloidosis
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Boston, MassachusettsAges 18–100 - NCT02685969Recruiting
Brain scan study of amyloid and brain sugar use
This study uses brain imaging to measure two things in the brain—amyloid protein and how the brain uses sugar. It may help researchers better understand early brain changes in people in the ALFA project.
Barcelona, CataloniaAges 45–75 - NCT06845644Recruiting
MRI scans to track nerve damage in neuropathy patients
This study uses MRI scans to look at nerve and muscle changes over time in people with inherited or acquired nerve conditions. It may help doctors better understand how these diseases progress.
MarseilleAges 18 years+ - NCT06932809RecruitingEarly Phase 1
Brain Uptake Study of a New Imaging Tracer
This study uses a special PET scan to see how a new tracer (18F-JSS20-183A) moves through the body and brain. It may help researchers learn more about brain diseases like Parkinson's and Alzheimer's.
San Francisco, CaliforniaAges 40–85 - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT06786676RecruitingPhase 1
Safety study of AS-S603 in healthy volunteers
This trial tests a new drug called AS-S603 in healthy volunteers to see if it is safe and how the body processes it. It is an early-phase study for people of Korean or Caucasian background.
SeoulAges 19–85 - NCT06757569Recruiting
New PET scan for detecting amyloid plaques in the brain
This study tests a newer, shorter PET scan to see if it can detect amyloid plaques (sticky protein clumps linked to memory loss) as well as the standard scan. It may help diagnose cognitive problems with less time in the scanner.
Toronto, OntarioAges 18 years+ - NCT06723015Enrolling by invitationPhase 2
Tau PET in anti-amyloid therapy for Alzheimer's
This study uses brain scans to see how anti-amyloid treatments affect tau protein buildup in people with early Alzheimer's. If you have mild cognitive impairment or mild Alzheimer's, you may be eligible to help understand how these treatments work.
Rochester, MinnesotaAges 50–90 - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT06618872Recruiting
Comparing tau and amyloid PET scans for memory problems
This study compares two types of brain PET scans (tau and amyloid) to see which one better helps diagnose memory problems. You may be eligible if you have mild cognitive impairment or mild dementia and your doctor has already ordered an amyloid PET scan.
Geneva, Canton of GenevaAges 50–85 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT06547099Recruiting
Understanding new blood markers in memory loss and dementia
This study is looking for older adults (60+) to help researchers better understand how to detect and track memory changes and dementia. Participants will provide blood samples and other health information over time to identify new markers that might help with early diagnosis.
St Louis, MissouriAges 60 years+ - NCT06481878Recruiting
Testing a stool test for Alzheimer’s markers
This study checks if Alzheimer’s-related proteins (amyloid and tau) can be found in stool samples. It may help develop a simple, non-invasive way to detect Alzheimer’s disease.
GrenobleAges 40 years+ - NCT03761381Recruiting
Eye scan study for mild Alzheimer’s and memory changes
This study uses detailed eye imaging (an eye scan) to look for signs related to probable Alzheimer’s disease and mild dementia. It may help researchers understand whether eye scans can reflect brain changes and improve detection.
Portland, OregonAges 55 years+ - NCT06439992Recruiting
New PET scan tracer to detect Alzheimer's in the brain
This study tests a new PET imaging tracer called Fluselenamyl to see how well it shows amyloid plaques (a protein linked to Alzheimer's) in the brain. It may help improve early diagnosis for people with Alzheimer's or support research in healthy volunteers.
St Louis, MissouriAges 18 years+
Hear when a new Amyloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloid?
- Yes. Clin2 currently lists 89 recruiting amyloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.